News HBM Holdings Limited

Equities

2142

KYG4403H1002

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.25 ^HKD	+5.04%		+20.19%	-35.57%

Apr. 02	HBM Holdings Returns to Profitability in 2023	MT
Mar. 28	HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HBM Holdings Returns to Profitability in 2023	Apr. 02	MT
Harbour BioMed Reports Full Year 2023 Financial Results	Mar. 28	PR
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	Feb. 27	MT
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	Jan. 24	MT
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	Jan. 23	CI
HBM to Swing to 2023 Profit	Jan. 19	MT
Harbour BioMed Announces Positive Profit Alert	Jan. 18	PR
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	Jan. 18	CI
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	Dec. 19	CI
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	Dec. 15	AQ
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	Dec. 15	MT
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	Dec. 01	CI
HBM Holdings Limited Announces Executive Changes	23-10-19	CI
HBM Swings to Profit in H1; Shares Up 6%	23-08-29	MT
HBM Gets US FDA Clearance to Hold Anti-Tumor Drug Trials in US	23-08-29	MT
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors	23-08-28	CI
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	23-08-08	PR
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	23-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News HBM Holdings Limited

Equities

2142

KYG4403H1002

Summary

Filters